Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

611

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Triple Negative Breast Cancer
Ovarian Cancer
Gastric Cancer
Colorectal Cancer
Glioblastoma
Biliary Tract Cancers
Pancreatic Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]